Asmanex Twisthaler · PIN 09857431 · 400 mcg/Metered Dose · dry-powder inhaler, 60 doses
General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check Health Canada brand searchPrivate plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Asmanex Twisthaler · DIN 09857431
Manufacturer: Organon Canada Inc.; listing date 2012-12-21
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Asmanex Twisthaler: Formulary list price $84.83 per unit (the source does not state the unit; exact figure $84.8280). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09857431)
Source record
DIN 09857431: Asmanex Twisthaler
Raw flags: sec3=Y
Item: 680400110; group id 717; item number 1773; lccId None; manufacturer id OCI
Source form: Pd Inh-60 Dose Pk; strength: 400mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $84.8280; ministry $84.8280
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09857431
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Therapeutic Notes (formulary)
NOTES: The general direction of the therapy of asthma has been toward the use of anti-inflammatory agents, especially inhaled steroids, which are not associated with systemic side effects to the same degree as oral steroids. The proper technique of inhalation or use of a spacer is very important to the efficacy of these agents. Physicians and pharmacists should ensure that patients are appropriately instructed in the use of these devices.
Shortage status: not checked (no credentials)